Results 201 to 210 of about 22,044 (247)

Plenary Abstracts Session & Oral Presentations

HemaSphere, Volume 9, Issue S1, June 2025.
wiley   +1 more source

Increased SARS-CoV-2 IgG4 has variable consequences dependent upon Fc function, Fc receptor polymorphism, and viral variant. [PDF]

Sci Adv
Aurelia LC, Purcell RA, Theisen RM, Kelly A, Esterbauer R, Ramanathan P, Lee WS, Wines BD, Hogarth PM, Juno JA, Allen LF, Bond KA, Williamson DA, Trevillyan JM, Trubiano JA, Nguyen TH, Kedzierska K, Wheatley AK, Kent SJ, Arnold KB, Selva KJ, Chung AW.   +21 more
europepmc   +1 more source

Poster Sessions

HemaSphere, Volume 9, Issue S1, June 2025.
wiley   +1 more source

Publication Only

HemaSphere, Volume 9, Issue S1, June 2025.
wiley   +1 more source

Impact of Vaccine-Elicited Anti-Spike IgG4 Antibodies on Fc-Effector Functions Against SARS-CoV-2. [PDF]

Viruses
Dionne K, Tauzin A, Bélanger É, Desfossés Y, Benlarbi M, Niu L, Beaudoin-Bussières G, Medjahed H, Bourassa C, Perreault J, Pazgier M, Bazin R, Finzi A.   +12 more
europepmc   +1 more source

Gene expression profiling in pure neural leprosy: insights into pathogenesis and diagnostic biomarkers. [PDF]

Front Immunol
de Athaide MM, Leal-Calvo T, Da Silva TP, Rosa TLSA, Ferreira H, Pascarelli BMO, Siquara de Sousa AC, Jardim MR, Pinheiro RO.   +8 more
europepmc   +1 more source

Clinical usefulness of anti-α3Gal immunoglobulin E assays for cetuximab-mediated anaphylaxis in head and neck cancer. [PDF]

Immunooncol Technol
Pointreau Y, Freneaux C, Bejan-Angoulvant T, Ternant D, Calais G, Watier H.   +5 more
europepmc   +1 more source

A novel long-acting relaxin-2 fusion, AZD3427, improves cardiac performance in non-human primates with cardiac dysfunction. [PDF]

Cardiovasc Res
Papworth M, Kulkarni S, Antonsson M, Sermadiras I, Hovdal D, Connolly K, Olsson J, Shukla A, Cotton P, Althage M, Paterson J, Martin E, Wolny M, Ferraro F, Sadowska A, Hao W, Larsson N, Backmark A, Marlow T, Perez R, Jermutus L, Omar S, George RT, Gabrielsen A, Pettersen D, Jennbacken K.   +25 more
europepmc   +1 more source

Prediction of human pharmacokinetics of Fc-engineered therapeutic monoclonal antibodies using human FcRn transgenic mice. [PDF]

MAbs
Haraya K, Ichikawa T, Murao N, Katada H, Kuramochi T.   +4 more
europepmc   +1 more source

A randomized, two-armed, double-blind, single-dose, cross-over, bioequivalence clinical trial to compare pharmacokinetic parameters and safety of recombinant human factor VIII with Fc fusion produced by AryoGen Pharmed Company versus Elocta^® (reference product) in previously treated patients with severe haemophilia A. [PDF]

Ann Hematol
Eghbali A, Eshghi P, Toogeh G, Alavi S, Badiei Z, Ghanavat M, Bordbar M, Bazrafshan A, Karimi K, Ahmadinejad M, Sabzvari A, Kafi H.   +11 more
europepmc   +1 more source